Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy-Reference-Cited by-同舟云学术

Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy

Published:2014-09-17 Issue:1 Volume:14 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Amanzada Ahmad,Goralczyk Armin D,Reinhardt Lars,Moriconi Federico,Cameron Silke,Mihm Sabine

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/content/pdf/10.1186/1471-2334-14-503.pdf

Reference43 articles.

1. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009, 361: 580-593. 10.1056/NEJMoa0808010.

2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001, 358: 958-965. 10.1016/S0140-6736(01)06102-5.

3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347: 975-982. 10.1056/NEJMoa020047.

4. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, PROVE3 Study Team: Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010, 362: 1292-1303. 10.1056/NEJMoa0908014.

5. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators: Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011, 364: 1207-1217. 10.1056/NEJMoa1009482.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EPO rs1617640 A>C is a Protective Factor for Chronic Obstructive Pulmonary Disease: A Case Control Study;Frontiers in Bioscience-Landmark;2023-09-24

2. The Functional Erythropoetin rs1617640 Gene Polymorphism does not Affect Life Expectancy of Patients with Peripheral Arterial Disease;Reviews in Cardiovascular Medicine;2023-07-13

3. EPO rs1617640 A>C is a protective factor for chronic obstructive pulmonary disease: a case control study;2022-10-11

4. Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies;The American Journal of Human Genetics;2022-09

5. Erythropoietin promoter polymorphism is associated with treatment efficacy and severe hematologic toxicity for platinum-based chemotherapy;Expert Opinion on Drug Metabolism & Toxicology;2021-02-07